OncoKB New Data Release - December 6, 2023
Contact OncoKB
Data Release v4.12
December 6, 2023
What's New
Updated therapeutic implications - Changed level of evidence
Level 1: PTEN oncogenic mutations in breast cancer promoted from Level 4 to Level 1 based on latest FDA-approval of Capivasertib + Fulvestrant (PMID: 37256976)
Drug(s) currently in OncoKB™: GSK2636771, AZD8186 (Level 4)
Level 1: AKT1 oncogenic mutations in breast cancer promoted from Level 3A to Level 1 based on latest FDA-approval of Capivasertib + Fulvestrant (PMID: 37256976)
Drug(s) currently in OncoKB™: Capivasertib (AKT1 E17K only; Level 3A)
Level 3A: KRAS G12A/D/R/S/V in pancreatic adenocarcinoma and non-small cell lung cancer promoted from Level 4 to Level 3A based on clinical data presented at ESMO 2023 of RMC-6236 (Abstract: Arbour, KC. et al. Abstract# 6520, Annals of Oncol. 2023)
Updated therapeutic implications - Addition of therapies for variants with a level of evidence
Level 1: Capivasertib + Fulvestrant added as a treatment for PIK3CA oncogenic mutations in breast cancer based on latest FDA-approval (PMID: 37256976)
Level 1: Repotrectinib for ROS1 fusions in non-small cell lung cancer promoted from Level 3A to Level 1 based on latest FDA-approval (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023)
Updated therapeutic implications - New alterations with a level of evidence
Level 3A: Cetuximab, Cetuximab + Chemotherapy, Panitumumab and Panitumumab + Chemotherapy added as a treatment for EGFR amplification in gastroesophageal adenocarcinoma based on data from a retrospective evaluation of EGFR-amplified gastroesophageal adenocarcinomas treated with EGFR inhibitors (PMID: 35349370)
Addition of 7 new genes:
FGF6 HSD3B1 IRF2 PAX3 PAX7 PDK1 ZNF217
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
